{
    "clinical_study": {
        "@rank": "119285", 
        "arm_group": {
            "arm_group_label": "Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Patients enrolled will receive the standard 3-dose treatment of sipuleucel-T, followed by treatment(s) of ipilimumab."
        }, 
        "brief_summary": {
            "textblock": "This is a clinical trial designed to quantify the immune response and determine the\n      tolerability and side effects of sipuleucel-T when given in combination with ipilimumab for\n      patients with advanced prostate cancer."
        }, 
        "brief_title": "Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer", 
        "condition": [
            "Prostate Cancer", 
            "Castrate Resistant Prostate Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects with advanced prostate cancer who are eligible to receive sipuleucel-T in\n             accordance with FDA approved labeling of sipuleucel-T\n\n          -  Subjects must understand and sign an informed consent form\n\n        Exclusion Criteria:\n\n          -  Subjects who are not eligible to receive sipuleucel-T"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "9", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 10, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01832870", 
            "org_study_id": "SIPIPI 2013"
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment", 
                "intervention_name": "sipuleucel-T", 
                "intervention_type": "Drug", 
                "other_name": "Provenge"
            }, 
            {
                "arm_group_label": "Treatment", 
                "intervention_name": "ipilimumab", 
                "intervention_type": "Drug", 
                "other_name": "Yervoy"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Marina del Rey", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "90292"
                }, 
                "name": "Prostate Oncology Specialists, Inc."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1 Study of Sipuleucel-T and Ipilimumab in Combination for Advanced Prostate Cancer", 
        "overall_official": {
            "affiliation": "Prostate Oncology Specialists, Inc.", 
            "last_name": "Mark Scholz, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "To quantify antigen-specific memory T cell response to sipuleucel-T and ipilimumab in combination.", 
                "measure": "Antigen-specific memory T cell response", 
                "safety_issue": "No", 
                "time_frame": "After last sipuleucel-T and last ipilimumab, and follow-up period, an expected average of 15 months"
            }, 
            {
                "description": "To quantify Antigen-specific T cell proliferation to PA2024, PAP and PHA when sipuleucel-T and ipilimumab are given in combination.\nPA2024 is a recombinant protein\nPAP: Prostatic acid phosphatase\nPHA: Phytohaemagglutinin, an assay control", 
                "measure": "Antigen-specific T cell proliferation to PA2024, PAP and PHA", 
                "safety_issue": "No", 
                "time_frame": "After last sipuleucel-T and last ipilimumab, and follow-up period, an expected average of 15 months"
            }, 
            {
                "description": "To quantify antibody responses against PA2024 and PAP.\nPA2024 is a recombinant protein\nPAP: Prostatic acid phosphatase", 
                "measure": "Antibody responses against PA2024 and PAP", 
                "safety_issue": "No", 
                "time_frame": "After last sipuleucel-T and last ipilimumab, and the follow-up period, an expected average of 15 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01832870"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To measure changes in PSA doubling time following treatment with sipuleucel-T and ipilimumab", 
                "measure": "Prostate-Specific Antigen (PSA) doubling time", 
                "safety_issue": "No", 
                "time_frame": "Duration of the study, an expected average of 18 months"
            }, 
            {
                "description": "To quantify time to PSA progression after treatment with sipuleucel-T and ipilimumab", 
                "measure": "Time to PSA progression", 
                "safety_issue": "No", 
                "time_frame": "Duration of the study, an expected average of 18 months"
            }, 
            {
                "description": "To quantify time to salvage therapy after treatment with sipuleucel-T and ipilimumab", 
                "measure": "Time to salvage therapy", 
                "safety_issue": "No", 
                "time_frame": "Duration of the study, an expected average of 18 months"
            }, 
            {
                "description": "To measure percentage PSA decline following treatment with sipuleucel-T and ipilimumab", 
                "measure": "Percentage PSA decline", 
                "safety_issue": "No", 
                "time_frame": "Duration of the study, an expected average of 18 months"
            }
        ], 
        "source": "Prostate Oncology Specialists, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Prostate Oncology Specialists, Inc.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}